Research2 days ago 4 min read
Selank shows modest anxiety reduction in small Russian trial
A 60-patient trial compared intranasal Selank to a benzodiazepine and to placebo.
by Editorial team
Design
Sixty adults with generalized anxiety disorder were randomized to intranasal Selank, medazepam, or placebo for 14 days.
Outcomes were measured using standard anxiety scales.
Findings
Selank produced modest reductions in anxiety scores, broadly comparable to the benzodiazepine but with fewer sedative side effects.
Effects did not persist meaningfully beyond the treatment window.
Limitations
The trial was small and conducted at a single site.
Replication in Western populations and with longer follow-up is lacking.